A2780CIS CELLS HUMAN OVARIAN CARCINOMA (C15-1313-650)

Cell Line Origin

Human ovarian carcinoma

Cell Line Description

This cisplatin-resistant cell line has been developed by chronic exposure of the parent cisplatin-sensitive A2780 cell line (Sigma catalogue no. 93112519) to increasing concentrations of cisplatin. A2780cis is cross-resistant to melphalan, adriamycin and irradiation. An increased ability to repair DNA damage as well as cytogenetic abnormalities has been observed. In order to retain resistance cisplatinum has to be added to the media every 2-3 passages. In addition to this matched pair of drug-sensitive/resistant cell lines an adriamycin-resistant cell line, A2780adr (Sigma catalogue no. 93112520), has been isolated from the same parental line A2780.

Application

2780cis human cell line has been used to study the cytotoxic effects of platinum (II) complexes and gold (I)-triphenylphosphine complexes with hypoxanthine-derived ligands. It has also been used to study the effects of cancer-cell specific oligopeptides.

Toxicity testing, drug resistance studies

DNA Profile

STR-PCR Data: Amelogenin: X
CSF1PO: 10,11
D13S317: 13
D16S539: 11,13
D5S818: 11
D7S820: 10
THO1: 6
TPOX: 8,10
vWA: 15,16

Culture Medium

RPMI 1640+ 2 mM Glutamine + 1 μm Cisplatin + 10% Fetal Bovine Serum FBS (cisplatinum only necessary every 2-3 passages).

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x10,000cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Cells will attach slowly after resuscitation and take up to 7 days to reach confluency. Recommendation: resuscitate cells in media without cisplatin. Add after subculture of attached cells.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Legal Information

Adriamycin is a registered trademark of RDF Pharmacia & Upjohn S.P.A.

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.

biological source: human ovary. growth mode: Adherent. karyotype: Modal no. 46. morphology: Epithelial. products: Not specified. receptors: Not specified. technique(s): cell culture | mammalian: suitable. relevant disease(s): cancer. shipped in: dry ice. storage temp.: −. 196°C.